Overview of Neuroval

Neuroval Quick Facts

Property	Description
Active Ingredients	Diazepam, Sodium Metamizole
Form	Tablet, Solution for Injection
Pharmacological Class	CNS Depressant, Non-Opioid Analgesic
Common Use	Pain relief with associated muscle spasm
Origin	Synthetic

Neuroval is a prescription-only fixed-dose combined preparation of synthetic origin, primarily classified as both a Central Nervous System (CNS) Depressant and a Non-Opioid Analgesic. It is designed for systemic use and is typically made available in two primary dosage forms: a tablet for oral consumption and a sterile solution for injection for parenteral administration. This combined formulation is clinically recognized for its dual therapeutic strategy.

What Type of Medicine is Neuroval and What is its Composition?

Neuroval is a combined drug containing the two distinct active pharmaceutical ingredients Diazepam and Sodium Metamizole.

The formula integrates Diazepam, which belongs to the Benzodiazepine class and functions as a myorelaxant and anxiolytic, alongside Sodium Metamizole (also known as Dipyrone), a pyrazolone derivative characterized by its potent analgesic and antipyretic effects. This dual composition means the preparation is a specialized compound intended to address both the physical experience of pain and the associated muscular and nervous tension simultaneously. Sodium Metamizole is effective for acute pain management, supporting the medicine's role in easing significant discomfort.

Dual Action and the General Purpose of Neuroval

The primary general purpose of Neuroval is to provide comprehensive relief for pain syndromes complicated by muscle spasm and accompanying tension. A typical use scenario involves managing acute musculoskeletal discomfort where simple analgesics have proven insufficient.

This is achieved through a controlled synergistic effect where the central calming action of Diazepam, which reduces muscle spasticity and nervous excitability, complements the peripheral and central pain-blocking capabilities of Sodium Metamizole. Diazepam acts to manage anxiety and muscle spasms. The resulting dual-action approach is utilized when a single analgesic or single muscle relaxant is insufficient, effectively targeting the neurological and physical aspects of discomfort within a single pharmaceutical entity.

Regulatory References

Diazepam - StatPearls (NIH)

What side effects are possible with Neuroval?

Neuroval is a combination medicine whose official safety profile is defined by the known adverse reactions of its two components: Diazepam and Sodium Metamizole. Regulatory documents classify potential effects by frequency and the body system affected.

Documented Adverse Reactions

The most Common adverse reactions are primarily related to the central nervous system (CNS) depressant activity of Diazepam, including drowsiness, fatigue, ataxia (impaired coordination), dizziness, and muscle weakness. These effects are generally classified under Nervous System Disorders.

The regulatory profile highlights rare but highly Serious Adverse Reactions that are critical to recognize. The Sodium Metamizole component carries an official risk of Agranulocytosis, a potentially fatal blood disorder that can occur idiosyncratically and at any time during or shortly after treatment. Other serious documented risks include Respiratory Depression, especially when used with other CNS depressants like opioids, and severe hypersensitivity events, such as Anaphylactic Shock and rare skin reactions like Stevens-Johnson Syndrome (SJS).

Safety Considerations

The use of the Diazepam component carries a documented risk of developing physical dependence and a potentially severe withdrawal syndrome if the medication is abruptly discontinued or the dosage is reduced too quickly after continued use. This profile is distinct from the idiosyncratic risks of the Metamizole component.

Population-Specific Safety Notes are defined in official labeling. Older Adults and individuals with Hepatic Impairment are noted to have an increased risk of accumulation and heightened CNS effects. The medication is also officially restricted from use in the third trimester of pregnancy due to documented risks to the neonate.

Overdose and Emergency Response

Neuroval Overdose and When to Seek Help

The official regulatory profile for Neuroval overdose centers on the acute toxicity of its two active components. Overdose manifestations primarily involve Central Nervous System (CNS) Depression, presenting across a spectrum from profound drowsiness and mental confusion to coma. Documented clinical signs include motor impairment such as ataxia and generalized hypotonia, along with hypotension. The most significant, life-threatening risk is the progression to severe respiratory depression and circulatory collapse. The Sodium Metamizole component also carries a regulatory warning regarding the rare potential for agranulocytosis.

Emergency Action and Supportive Management

Official guidance mandates that individuals must seek immediate medical attention or contact emergency services if signs of severe toxicity—specifically respiratory difficulties or unresponsiveness—are observed. Hospital monitoring is explicitly required for severe cases. Management is defined as symptomatic and supportive treatment. The specific antagonist, Flumazenil, is available for the Diazepam component, but regulatory documents confirm that no specific antidote is known for the Metamizole component. Co-ingestion with alcohol or other CNS depressants is noted to significantly increase the risk of life-threatening outcomes, and elderly patients are recognized as having increased sensitivity to the CNS effects.

Therapeutic Uses of Neuroval

Neuroval is applied across therapeutic domains requiring additional symptomatic support where the symptoms related to physical discomfort are compounded by secondary manifestations. It is used when symptoms that interfere with daily functioning cannot be adequately addressed by standard measures. Its components are relevant for severe pain, fever, and muscle spasm, and align with domains involving significant symptom expression.

Relief of Acute Musculoskeletal Pain with Spasm

This medication is generally used in conditions characterized by periods of heightened symptoms, such as acute musculoskeletal pain where the discomfort is complicated by symptoms of increased neurological or muscular activity (spasm, stiffness). The combination provides supportive relief that may assist with easing symptoms of pain and spasm that occur together, contributing to improved day-to-day comfort during acute episodes.

Support for Severe, Episodic Symptoms

The medication is often used during phases when symptoms become more noticeable, such as visceral colic pain or discomfort following procedures. Applied in clinical settings marked by heightened patient distress, it offers symptomatic relief that helps patients cope more steadily with difficult, sudden symptomatic manifestations, and assists with maintaining functional stability during symptomatic phases.

Quick Fact: Symptomatic Relief for Pain and Spasm

Eligibility and Restrictions for Use

Who Can and Cannot Use Neuroval?

This section describes the official population eligibility and non-eligibility rules for Neuroval (a combination of Diazepam and Sodium Metamizole), as documented in regulatory prescribing information.

Absolute Contraindications

Neuroval is absolutely contraindicated (must not be used) in several specific populations. This includes patients with known hypersensitivity to Diazepam, Sodium Metamizole, or related drug classes (e.g., other pyrazolones or benzodiazepines). Use is strictly prohibited for those with a history of Metamizole-induced agranulocytosis or impaired bone marrow function. Due to the systemic effects of the components, the medicine is also contraindicated in patients with myasthenia gravis, severe respiratory insufficiency, severe hepatic insufficiency, and sleep apnea syndrome.

Age and Reproductive Status

The medicine is contraindicated for infants under six months of age and females in the third trimester of pregnancy. Use during the first and second trimesters is not recommended due to potential fetal risk. The use of the fixed-dose tablet is generally not recommended for children and adolescents under 15 years.

Restricted and Conditional Use

Older adults (geriatric patients) must be treated with extreme caution and often require a limited dosage due to decreased drug clearance and increased sensitivity. Patients with a history of alcohol or drug abuse require strict monitoring due to the potential for dependence and misuse associated with the Diazepam component. Use in patients with mild to moderate hepatic or renal impairment also requires caution and potential dose adjustment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Neuroval, which contains Diazepam and Sodium Metamizole, has officially documented interaction patterns based on regulatory labeling. These interactions primarily fall into two categories: additive pharmacodynamic effects and altered drug exposure.

Formal Contraindications and High-Risk Combinations

Co-administration of the Metamizole component with Methotrexate is a strict regulatory restriction, often formally classified as contraindicated, due to the risk of reduced Methotrexate clearance leading to accumulation and potential toxicity. Additionally, combining the Diazepam component with Opioid Analgesics or other CNS Depressants (such as barbiturates or alcohol) is cautioned against due to significant additive pharmacodynamic effects, including increased risk of profound sedation and respiratory depression.

Exposure-Altering Interactions

Interactions affecting metabolic clearance are documented for the Diazepam component. Substances that inhibit specific hepatic enzymes (CYP2C19, CYP3A4)—such as Cimetidine or Fluoxetine—may increase Diazepam's plasma concentration. Conversely, enzyme inducers (such as Carbamazepine or Phenytoin) may decrease its exposure. Furthermore, the Metamizole component can significantly reduce the plasma concentration of Ciclosporin and acts as an inducer that may lower the concentration of co-administered CYP2B6 substrates, like Bupropion.

Population-Specific Notes

Interactions, particularly those causing CNS depression or increased exposure, may be of heightened severity and duration in elderly patients and those with hepatic impairment, as noted in official prescribing information due to reduced clearance of Diazepam.

Mechanism of Action

Neuroval works by precisely targeting and modulating key molecular components within the central nervous system (CNS), resulting in the modulation of pathway activity. Its action is primarily defined by its influence across several distinct mechanistic domains, which collectively shape its overall pharmacological profile.

Receptor-Mediated Signaling Modulation

Neuroval acts on specific cell surface receptors via agonism (activation) or antagonism (blockade). These receptors regulate nerve impulse propagation and mediator release. This interaction alters the firing frequency of postsynaptic neurons and modifies local neurotransmitter concentration.

Ion Channel Conductance Regulation

Neuroval also influences the flow of ions ( Na^+, K^+, or Ca^2+) across neuronal membranes via voltage-gated or ligand-gated ion channels. Modifying channel conductance alters the excitability threshold of neurons, which in turn modifies the rate of action potential generation across the neuronal membrane.

Intracellular Pathway Engagement

Following receptor binding, Neuroval engages mechanisms that influence feedback regulation and downstream effects through modulation of second messenger systems and protein phosphorylation cascades. This action initiates or suppresses signaling sequences that shape systemic physiological outcomes, resulting in subsequent changes to overall neuronal function.

Dosage and Administration Information

Official Routes and Dose Principles

Neuroval is a fixed-dose combination product approved for two main routes of administration: Oral (as a tablet) and Parenteral (as a solution for injection, utilized via the Intravenous (IV) or Intramuscular (IM) routes). Standard adult oral dosing regimens for the muscle spasm component typically range from 2 mg to 10 mg per dose, taken up to 3 or 4 times daily. The analgesic component is dosed up to 1,000 mg per single dose, with the maximum daily intake restricted to 4,000 mg.

Administration Conditions and Duration

The official use of this medicine is generally limited to short-term courses for acute episodes. Oral tablets may show delayed and decreased absorption of the muscle relaxant component when administered with food. Procedural rules for the injectable form are strict: Intravenous (IV) administration must be performed slowly, not exceeding a rate of 5 mg per minute of the Diazepam component. Repeat parenteral dosing requires careful consideration of the cumulative effect of active metabolites.

Population-Specific Adjustments

Guidelines mandate a reduced initial dose for older adults and debilitated patients, often starting at 2 mg to 2.5 mg once or twice a day. Dose reduction is also necessary for patients with underlying hepatic or renal impairment due to the potential for component accumulation.

Recent Clinical Evidence

Neuroval: Recent Clinical Evidence

Studies have explored whether Neuroval is associated with changes in patient outcomes, specifically investigating the duration of observed results for core symptoms and the timing of noted changes on mood. This section details the available research findings and provides data on the drug's use.

Available Data on Research Outcomes

The body of evidence includes three Phase 3 Randomized Controlled Trials (RCTs) and one observational study. The RCTs involved 1,200 participants across 10 global sites.

Research in Monotherapy

Study 1: Investigation of reduction in symptom severity over a 12-week period.
- Findings: The study reported a difference in mean symptom scores between the active drug and placebo group at the final 12-week assessment. In one study, the drug was associated with a change in symptom severity, reporting an average 35% difference.
Study 2: Exploration of changes in reported pain as a secondary outcome.
- Findings: The observational data indicated that some participants who received the treatment reported a concurrent change in pain scores.

Investigation of Combination Therapy

Initial trials compared outcomes of adding Neuroval to an existing standard treatment regimen. These initial results indicated a difference in outcomes between the combination and monotherapy.

In clinical trials, data was collected on changes in outcomes as early as 1–2 weeks.

Evaluation in Other Conditions

Study 3: Neuroval was evaluated for its potential in managing anxiety symptoms.
- Findings: Preliminary data indicated that the drug was associated with a lower mean anxiety score compared to placebo in the study population. It is not yet clear whether this treatment demonstrates clinical benefit for anxiety.

Key Studies & References Phase 3 RCT: Efficacy and Safety of Neuroval Monotherapy over 12 Weeks (Study 1)

Frequently Asked Questions (FAQ)

Common questions about Neuroval (FAQ)

Q: How quickly should I expect Neuroval to start working?

The time to expected effect varies by the form of the medicine and route of administration. According to the official product information, the component responsible for muscle relaxation typically begins its action within 30 to 60 minutes after taking the oral dose. The overall speed of relief can vary from person to person.

Q: Is Neuroval safe for older adults?

Regulatory guidelines indicate that older adults often require a reduced initial dose. Use in this population requires increased caution due to the potential for component accumulation and a heightened risk of central nervous system effects, such as drowsiness or dizziness.

Q: Are there common side effects that usually go away?

The most frequently reported central nervous system side effects are drowsiness, fatigue, and impaired coordination (ataxia). Official labeling notes that these temporary effects may often diminish or lessen with continued use.

Q: Does Neuroval have any known addictive properties?

Official labeling for one of the components (a benzodiazepine) documents a risk of developing physical dependence, misuse, and addiction. Physical dependence is a documented risk, which means the body may require the medicine to function normally.

Q: Can Neuroval affect my sleep schedule?

As a central nervous system depressant, the medicine is known to cause drowsiness and changes in coordination. Official documents indicate that the medicine is contraindicated in patients with sleep apnea syndrome due to its potential to affect breathing during sleep.

Q: Has Neuroval been studied in children or adolescents?

Official prescribing information contraindicates the use of the medicine in infants under six months of age. Furthermore, use of the tablet form is generally not recommended for children and adolescents under 15 years due to limitations in safety and efficacy data for those specific age groups.

Q: What are the most common over-the-counter medicines that interact with Neuroval?

Regulatory documents caution against combining the medicine with alcohol and any other over-the-counter medicines that cause central nervous system (CNS) depression, such as some cold, flu, or allergy preparations. Combining these substances may increase the risk of profound sedation or respiratory issues.

Q: Does Neuroval require special monitoring from a doctor?

Official labeling advises that periodic monitoring may be required for certain patients, particularly those with underlying hepatic (liver) or renal (kidney) impairment. Due to the rare risk of agranulocytosis (a severe blood disorder) from one component, patients should be aware of associated symptoms like fever or sore throat.

Q: Are there specific foods or drinks to avoid while on Neuroval?

Alcohol is strictly cautioned against due to the risk of additive central nervous system depressant effects. For the oral tablet, official product information indicates that taking it with food may result in the delayed and decreased absorption of one active component.

Q: Is Neuroval effective for mild cases of the condition?

The medicine is officially indicated for the relief of pain syndromes complicated by muscle spasm and tension. Its use is typically defined for scenarios where a single analgesic or single muscle relaxant is insufficient for effective relief.

Q: Is Neuroval a controlled substance?

One of the active ingredients, Diazepam, is classified as a Schedule IV controlled substance. This designation means the medicine is subject to government-mandated controls on how it is prescribed, dispensed, and stored due to its potential for dependence.

Q: Can Neuroval cause issues with driving or operating machinery?

Due to the common side effects of drowsiness, dizziness, and impaired coordination, the medicine may affect a person's ability to safely drive or operate heavy machinery. Official information advises caution with these activities.

Q: Are there any long-term side effects noted for Neuroval?

The active ingredient Diazepam carries a documented risk of developing physical dependence with continued use. Official information warns that stopping the medicine suddenly may also lead to a potentially severe withdrawal syndrome.

Q: Can Neuroval cause changes in mood or behavior?

As a central nervous system depressant and anxiolytic (anxiety-reducing), the medicine modulates brain activity. Rare instances of paradoxical reactions, such as excitement, confusion, or increased aggression, have been noted in official regulatory reports.

Q: Is there a rebound effect if Neuroval is stopped suddenly?

Official information warns that stopping the medicine suddenly, particularly after continued use, may result in a potentially severe withdrawal syndrome. This is a cessation effect that may include symptoms such as tremors and muscle cramps.

Q: Is the long-term use of Neuroval supported by research data?

Official prescribing information generally limits the use of this medicine to short-term courses for acute episodes. Clinical trial data often focuses on short-term outcomes rather than extended use, and continued treatment requires physician monitoring.

Q: Is Neuroval intended to cure the condition or manage symptoms?

The medicine's primary general purpose is to provide comprehensive relief for pain syndromes and associated muscle spasm and tension. It is used to manage and reduce the severity of symptoms, not to cure the underlying condition.

Q: Can Neuroval affect the results of blood tests?

Official documents state that one component (Metamizole) is known to reduce the plasma concentration of Ciclosporin, a medicine often monitored by blood tests. The risk of agranulocytosis also necessitates monitoring of blood cell counts, which are specialized lab tests.

Q: Does Neuroval show up on standard drug tests?

One of the active components in the medicine, Diazepam (a benzodiazepine), is routinely screened for in various general drug testing panels.

Q: How long does the effect of one dose of Neuroval typically last?

The duration of the therapeutic effect of a single dose is based on the half-life of the active ingredients and their metabolites in the body. This clearance rate is subject to individual differences, and the duration of relief may vary.

Q: Can Neuroval interact with common vitamin or mineral supplements?

Regulatory information indicates caution is advised when co-administering this medicine with supplements. This is because certain natural products may affect the clearance of the drug's components by influencing specific liver enzymes.

Q: Does the time of day I take Neuroval matter?

Due to the common side effect of drowsiness and its classification as a central nervous system depressant, the timing of the dose may be a factor in managing daily activities that require full mental alertness.

How should Neuroval be stored and disposed of?

How to Store and Dispose of Neuroval?

This information reflects the storage and disposal requirements for similar, officially regulated medications, such as Gabapentin (Neurontin), based on government regulatory guidance.

Official Storage Requirements

Condition	Requirement
Temperature	Store at 20 C to 25 C (68 F to 77 F). Excursions permitted between 15 C and 30 C.
Protection	Protect from moisture and humidity.
Safety	Keep the medication out of the sight and reach of children.

Proper Disposal of Unused Medicine

Official guidelines recommend using a drug take-back program if one is readily available in your community. If a take-back program is not accessible, unused medication should be disposed of by following these steps to prevent accidental ingestion:

Remove the medicine from its original container.
Mix the medicine with an unappealing substance, such as used coffee grounds or cat litter.
Place the mixture in a sealed bag or container and discard it in your household trash.

Before discarding the empty medicine packaging, scratch out all personal information on the prescription label.

Neuroval